COMMUNIQUÉS West-GlobeNewswire

Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
29/04/2019
Voyager’s vectorized antibody program directed against tau demonstrates antibody distribution and expression levels in specific cell types that further facilitate studies with a vectorized antibody in animal models of [...]
Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019
29/04/2019
Axsome to host conference call and webcast on Thursday, May 9, 2019 at 8:00 AM Eastern Time NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical [...]
Share buy-back week 17/2019
29/04/2019
Announcement 29 April 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling [...]
ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
29/04/2019
SINGAPORE, April 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical stage oncology and immunology focused biopharmaceutical company developing novel therapeutics for global markets, [...]
ViroGates Releases First Quarter 2019 Results
29/04/2019
Company announcement no. 8-2019 Birkerød, 29 April 2019 ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems for emergency departments in hospitals, today reported financial results for the [...]
Revised Financial Calendar 2019
29/04/2019
Company announcement no. 7-2019 Birkerød, 29 April 2019 ViroGates A/S (Nasdaq First North Denmark: VIRO) has revised its financial calendar for 2019: 20 March Deadline for submission of business to be transacted at the [...]
Olainfarm signs a new 3 million euro worth supply contract with the World Health Organization
29/04/2019
JSC Olainfarm has won the International World Health Organization (WHO) tender for the supply of anti-tuberculosis agent PASS sodium in 2019 - 2020. Based on the results of the tender, WHO and Latvian pharmaceutical [...]
Remedent Inc. strengthened its participation in the global dental venture of tomorrow Metrics in Balance NV
29/04/2019
GHENT, Belgium, April 29, 2019 (GLOBE NEWSWIRE) -- On March 29 th , 2019 Remedent Inc. (OTCBB:REMI.OB) participated, through its 99,99% Belgian daughter company REMEDENT NV, in the contribution in kind of the Belgian [...]
Wildflower mise en avant dans la publication de NetworkNewsWire sur la croissance exponentielle de l'industrie du cannabis
29/04/2019
NEW YORK, 29 avr. 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Wildflower Brands Inc. (CSE : SUN) (OTCQB : WLDFF) a annoncé aujourd'hui son apparition dans une rubrique éditoriale publiée par NetworkNewsWire (« NNW »), [...]
Mereo BioPharma Group Plc ("Mereo" or the "Company" or the "Group") Preliminary Results for the Year Ended December 31, 2018 -- Strong Operational Progress
29/04/2019
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April [...]
Nicox to Present at Upcoming Pharmaceutical Industry and Financial Events
29/04/2019
For Information Nicox to Present at Upcoming Pharmaceutical Industry and Financial Events April 29, 2019 Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, [...]
Nicox : Participation à des conférences d’industrie pharmaceutique et financière
29/04/2019
Pour Information Nicox : Participation à des conférences d’industrie pharmaceutique et financière 29 Avril Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, éligible PEA-PME), une société [...]
Santhera Reports Strong Top-line Growth for 2018 and the Successful Expansion of its Rare Disease Pipeline
29/04/2019
Pratteln, Switzerland, April 29, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces the Group's audited financial results for 2018. The Company reports a 38% increase in net revenues year-on-year to CHF 31.7 million [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
29/04/2019
Regulated information Gosselies, Belgium, 29 April 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
29/04/2019
Information réglementée Gosselies, Belgique, le 29 avril 2019, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins médicaux [...]
Addex to Announce 2018 Full Year Audited Results on April 30, 2019
29/04/2019
Geneva, Switzerland, April 29, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will report its full-year audited [...]
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
29/04/2019
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Philips delivers Q1 sales of EUR 4.2 billion, with 2% comparable sales growth; income from continuing operations increased to EUR 171 million and Adjusted EBITA margin improved to 8.8%
29/04/2019
April 29, 2019 First-quarter highlights • Sales in the quarter amounted to EUR 4.2 billion, with 2% comparable sales growth • Comparable order intake increased 2% • Income from continuing operations increased to EUR 171 [...]
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
27/04/2019
FDA approves Praluent ® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause [...]

Pages